RE:RE:RE:Nice try Float in KentuckyInsolvent might be a little harsh. They should have enough cash to see them through the next few months if no unanticipated expense hits them out of the blue. The money isn't there for the phase 2 trial so until that issue is solved the market will remain skeptical. My guess is that management is waiting for all the HC approvals for the trial to be finalized and then they will approach the capital markets with a proposal to hold a brokered PP at the best terms they can get. If patient 6's results show promise then that will just be a bonus in their negotiations. It's too bad shareholders are feeling let down by the uncertainty that this company seems to surround itself with. We can point the finger at a company that functions without a strong CEO at its helm. Dr. Mandel is a capable science officer but as a CEO he sucks. He is not a natural born promoter and that is exactly what TLT needs right now. Apart from 1 mention in a PR where else has the 5th patient's 9 month results been exploited?